longbridgelongbridge
  • Products
  • Fees
longbridge
  • Home
  • Discover
    Discover
    Global MarketsStock ScreenerFinancial Calendar
  • News & Info
    News & Info
    NewsInsightsLiveAcademy
  • Watchlist
  • Trade
  • Notification
  • LongbridgeAI
Home
Discover
News & Info
Watchlist
Trade
LongbridgeAI
Quote ListQuote List

Viridian Therapeutics(VRDN.US)

Last Updated 19:00:00 ET
longbridge loading
News
Financials
Overview

How Investors May Respond To Viridian Therapeutics (VRDN) Debt Repayment And WuXi Manufacturing Pact

Simplywall·05/31/2026 01:18
US
VRDN
+1.30%
US
WXXWY
+2.33%
HK
02269
+3.81%
Simplywall·05/31/2026 01:18
US
VRDN
+1.30%
US
WXXWY
+2.33%
HK
02269
+3.81%

Viridien: Availability of the preparatory documents for the Combined General Meeting | CGG Stock News

StockTitan·05/13/2026 09:40
US
VRDN
+1.30%
StockTitan·05/13/2026 09:40
US
VRDN
+1.30%

Viridien: Information on the total number of voting rights and shares | CGG Stock News

StockTitan·05/12/2026 15:30
US
VRDN
+1.30%
StockTitan·05/12/2026 15:30
US
VRDN
+1.30%

Barclays Releases a Buy Rating on Viridien (0RI9)

Tip Ranks·05/08/2026 11:25
US
VRDN
+1.30%
Tip Ranks·05/08/2026 11:25
US
VRDN
+1.30%

Viridien (0RI9) Receives a Rating Update from a Top Analyst

Tip Ranks·05/08/2026 10:05
US
VRDN
+1.30%
Tip Ranks·05/08/2026 10:05
US
VRDN
+1.30%

Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million | VRDN Stock News

StockTitan·05/07/2026 03:15
US
VRDN
+1.30%
US
BBH
-0.17%
US
IBB
+0.10%
StockTitan·05/07/2026 03:15
US
VRDN
+1.30%
US
BBH
-0.17%
US
IBB
+0.10%
© 2026 Longbridge|Disclaimer

Event Tracking

May26
Viridian Therapeutics Signs Five-Year Manufacturing Agreement for Veligrotug with WuXi Biologics
20:08
May13
Fairmount Healthcare Fund II Acquires Shares of Viridian Therapeutics for 20 Million USD
20:32
May8
Kepler Capital Analyst Maintains Buy Rating on Viridien
02:22
May6
Viridian Therapeutics released FY2026 Q1 earnings on May 5 (EST), actual revenue USD 141K (forecast USD 27.75K), actual EPS USD -0.9003 (forecast USD -1.0889)
03:00
May5
Viridian Therapeutics Announces Phase 3 Trial Results for Elegrobart in Thyroid Eye Disease
14:55
Viridian Therapeutics' Drug Elegrobart Meets Primary Endpoint in Phase II Trial
11:01

Schedules & Filings

Schedules
Filings
May5
Earning Release(EST)

FY2026 Q1 Earning Release (USD) Revenue 141 K, Net Income -92.03 M, EPS -0.9003

Feb26
Earning Release(EST)

FY2025 Q4 Earning Release (USD) Revenue 132 K, Net Income -101.07 M, EPS -1.0709

Nov5
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 70.57 M, Net Income -28.17 M, EPS -0.3444

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
CAST
1.550
+140.68%
+0.906
CUPR
3.970
+64.73%
+1.560
UBXG
7.870
+64.30%
+3.080
HSPTR
0.4604
+64.14%
+0.180
SPCL
51.260
+56.56%
+18.519
VSME
1.690
+52.25%
+0.580
EDHL
8.640
+44.48%
+2.660
BYAH
1.470
+40.00%
+0.420
FRD
34.720
+31.61%
+8.340
ASTN
6.000
+31.29%
+1.430
View More